TriSalus Life Sciences (NASDAQ:TLSI) Upgraded to Hold at Zacks Research

TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by Zacks Research to a “hold” rating in a research note issued to investors on Thursday, Zacks reports.

A number of other equities research analysts have also weighed in on TLSI. Lake Street Capital decreased their target price on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Friday, August 7th. Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd. Finally, HC Wainwright began coverage on TriSalus Life Sciences in a report on Wednesday. They issued a “buy” rating and a $11.00 price objective for the company. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $8.67.

TriSalus Life Sciences Trading Down 0.9%

Shares of TLSI opened at $4.66 on Thursday. TriSalus Life Sciences has a 1-year low of $2.20 and a 1-year high of $7.95. The company has a 50-day moving average of $4.75 and a 200 day moving average of $4.33. The firm has a market capitalization of $286.96 million, a price-to-earnings ratio of -3.58 and a beta of 0.44. The company has a debt-to-equity ratio of 5.05, a current ratio of 5.35 and a quick ratio of 4.97.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). The company had revenue of $11.41 million during the quarter, compared to analysts’ expectations of $10.27 million. On average, research analysts expect that TriSalus Life Sciences will post -0.31 EPS for the current year.

Institutional Investors Weigh In On TriSalus Life Sciences

Hedge funds have recently made changes to their positions in the stock. First Light Asset Management LLC raised its holdings in TriSalus Life Sciences by 29.3% in the second quarter. First Light Asset Management LLC now owns 6,552,491 shares of the company’s stock worth $29,814,000 after purchasing an additional 1,485,664 shares in the last quarter. Corient Private Wealth LP grew its position in shares of TriSalus Life Sciences by 61.7% in the 2nd quarter. Corient Private Wealth LP now owns 147,152 shares of the company’s stock worth $670,000 after buying an additional 56,152 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $4,550,000. Bank of America Corp DE bought a new position in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $934,000. Finally, BlackRock Inc. purchased a new stake in TriSalus Life Sciences during the second quarter valued at approximately $12,099,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

More TriSalus Life Sciences News

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and an $11.00 price target, implying approximately 135.5% upside from the referenced $4.67 share price. The recommendation provides new analyst visibility and supports the bullish case for TLSI. HC Wainwright initiates coverage of TriSalus Life Sciences with a Buy rating
• Positive Sentiment: HC Wainwright’s forecasts point to improving long-term profitability. The firm estimates EPS of $0.09 in fiscal 2028, $0.57 in 2029 and $1.02 in 2030, suggesting expectations for substantial earnings growth as TriSalus expands its business.
• Neutral Sentiment: The analyst still expects losses through fiscal 2027, including EPS of negative $0.31 for 2026 and negative $0.28 for 2027. Quarterly loss estimates improve from negative $0.12 in the third quarter of 2026 to negative $0.02 in the fourth quarter of 2027, indicating gradual progress but continued reliance on execution and financing before profitability.
• Neutral Sentiment: Reported short interest was listed at zero shares as of September 10, unchanged from the prior period. This indicates no measurable short-squeeze setup, but also no significant disclosed bearish short positioning.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.